153 related articles for article (PubMed ID: 16329150)
1. Reduction in tamoxifen-induced CYP3A2 expression and DNA adducts using antisense technology.
Mahadevan B; Arora V; Schild LJ; Keshava C; Cate ML; Iversen PL; Poirier MC; Weston A; Pereira C; Baird WM
Mol Carcinog; 2006 Feb; 45(2):118-25. PubMed ID: 16329150
[TBL] [Abstract][Full Text] [Related]
2. Formation of tamoxifen-DNA adducts in multiple organs of adult female cynomolgus monkeys dosed with tamoxifen for 30 days.
Schild LJ; Divi RL; Beland FA; Churchwell MI; Doerge DR; Gamboa da Costa G; Marques MM; Poirier MC
Cancer Res; 2003 Sep; 63(18):5999-6003. PubMed ID: 14522927
[TBL] [Abstract][Full Text] [Related]
3. Tamoxifen-DNA adduct formation in rat liver determined by immunoassay and 32P-postlabeling.
Divi RL; Osborne MR; Hewer A; Phillips DH; Poirier MC
Cancer Res; 1999 Oct; 59(19):4829-33. PubMed ID: 10519392
[TBL] [Abstract][Full Text] [Related]
4. The aromatase inactivator 4-hydroxyandrostenedione (4-OH-A) inhibits tamoxifen metabolism by rat hepatic cytochrome P-450 3A: potential for drug-drug interaction of tamoxifen and 4-OH-A in combined anti-breast cancer therapy.
Dehal SS; Brodie AM; Kupfer D
Drug Metab Dispos; 1999 Mar; 27(3):389-94. PubMed ID: 10064571
[TBL] [Abstract][Full Text] [Related]
5. Identification of tamoxifen-DNA adducts in monkeys treated with tamoxifen.
Shibutani S; Suzuki N; Laxmi YR; Schild LJ; Divi RL; Grollman AP; Poirier MC
Cancer Res; 2003 Aug; 63(15):4402-6. PubMed ID: 12907611
[TBL] [Abstract][Full Text] [Related]
6. c-Myc antisense limits rat liver regeneration and indicates role for c-Myc in regulating cytochrome P-450 3A activity.
Arora V; Knapp DC; Smith BL; Statdfield ML; Stein DA; Reddy MT; Weller DD; Iversen PL
J Pharmacol Exp Ther; 2000 Mar; 292(3):921-8. PubMed ID: 10688605
[TBL] [Abstract][Full Text] [Related]
7. Inefficient repair of tamoxifen-DNA adducts in rats and mice.
Kim SY; Suzuki N; Laxmi YR; Shibutani S
Drug Metab Dispos; 2006 Feb; 34(2):311-7. PubMed ID: 16299164
[TBL] [Abstract][Full Text] [Related]
8. Effect of N,N-didesmethyltamoxifen upon DNA adduct formation by tamoxifen and alpha-hydroxytamoxifen.
Gamboa da Costa G; Marques MM; Fu X; Churchwell MI; Wang YP; Doerge DR; Beland FA
Cancer Lett; 2007 Nov; 257(2):191-8. PubMed ID: 17765393
[TBL] [Abstract][Full Text] [Related]
9. Investigation of the influence of modulation of P-glycoprotein by a multiple dosing regimen of tamoxifen on the pharmacokinetics and toxicodynamics of doxorubicin.
Darvari R; Boroujerdi M
Cancer Chemother Pharmacol; 2005 Nov; 56(5):497-509. PubMed ID: 15937726
[TBL] [Abstract][Full Text] [Related]
10. Tamoxifen-induced antitumorigenic/antiestrogenic action synergized by a selective aryl hydrocarbon receptor modulator.
McDougal A; Wormke M; Calvin J; Safe S
Cancer Res; 2001 May; 61(10):3902-7. PubMed ID: 11358803
[TBL] [Abstract][Full Text] [Related]
11. Effects of chronic administration of tamoxifen and toremifene on DNA adducts in rat liver, kidney, and uterus.
Li D; Dragan Y; Jordan VC; Wang M; Pitot HC
Cancer Res; 1997 Apr; 57(8):1438-41. PubMed ID: 9108442
[TBL] [Abstract][Full Text] [Related]
12. Formation of tamoxifen-DNA adducts in human endometrial explants exposed to alpha-hydroxytamoxifen.
Kim SY; Suzuki N; Laxmi YR; McGarrigle BP; Olson JR; Sharma M; Sharma M; Shibutani S
Chem Res Toxicol; 2005 May; 18(5):889-95. PubMed ID: 15892583
[TBL] [Abstract][Full Text] [Related]
13. Hepatic DNA adduct dosimetry in rats fed tamoxifen: a comparison of methods.
Schild LJ; Phillips DH; Osborne MR; Hewer A; Beland FA; Churchwell MI; Brown K; Gaskell M; Wright E; Poirier MC
Mutagenesis; 2005 Mar; 20(2):115-24. PubMed ID: 15755801
[TBL] [Abstract][Full Text] [Related]
14. Biotransformation of letrozole in rat liver microsomes: effects of gender and tamoxifen.
Tao X; Piao H; Canney DJ; Borenstein MR; Nnane IP
J Pharm Biomed Anal; 2007 Feb; 43(3):1078-85. PubMed ID: 17045772
[TBL] [Abstract][Full Text] [Related]
15. Determination of tamoxifen--DNA adducts in leukocytes from breast cancer patients treated with tamoxifen.
Umemoto A; Monden Y; Lin CX; Abdul-Momen M; Ueyama Y; Komaki K; Laxmi YR; Shibutani S
Chem Res Toxicol; 2004 Dec; 17(12):1577-83. PubMed ID: 15606132
[TBL] [Abstract][Full Text] [Related]
16. NTP toxicology and carcinogenesis studies of 3,3',4,4',5-pentachlorobiphenyl (PCB 126) (CAS No. 57465-28-8) in female Harlan Sprague-Dawley rats (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 2006 Jan; (520):4-246. PubMed ID: 16628245
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic effect of tamoxifen and energy-modulating vitamins on carbohydrate-metabolizing enzymes in breast cancer.
Perumal SS; Shanthi P; Sachdanandam P
Cancer Chemother Pharmacol; 2005 Jul; 56(1):105-14. PubMed ID: 15726365
[TBL] [Abstract][Full Text] [Related]
18. Mutagenic potential of alpha-(N2-deoxyguanosinyl)tamoxifen lesions, the major DNA adducts detected in endometrial tissues of patients treated with tamoxifen.
Terashima I; Suzuki N; Shibutani S
Cancer Res; 1999 May; 59(9):2091-5. PubMed ID: 10232593
[TBL] [Abstract][Full Text] [Related]
19. Accomodation of S-cis-tamoxifen-N(2)-guanine adduct within a bent and widened DNA minor groove.
Shimotakahara S; Gorin A; Kolbanovskiy A; Kettani A; Hingerty BE; Amin S; Broyde S; Geacintov N; Patel DJ
J Mol Biol; 2000 Sep; 302(2):377-93. PubMed ID: 10970740
[TBL] [Abstract][Full Text] [Related]
20. Molecular and pharmacokinetic evaluation of rat hepatic and gastrointestinal cytochrome p450 induction by tamoxifen.
Cotreau MM; von Moltke LL; Harmatz JS; Greenblatt DJ
Pharmacology; 2001; 63(4):210-9. PubMed ID: 11729359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]